Viatical Settlement

A viatical settlement is the sale of an in-force life insurance policy by a policyholder with a terminal illness to a third-party buyer for an immediate cash payment, typically 50–95% of the death benefit. Named from the Latin viaticum (travel money), it allows the dying to monetize their insurance while living, though it extinguishes the death benefit and creates complex tax and regulatory issues.

The origin and ethical context

Viatical settlements emerged in the 1980s during the AIDS crisis, when terminally ill patients held substantial life insurance but faced massive medical bills and wanted to enjoy remaining life without financial desperation. Selling the policy to an investor—who would eventually collect the death benefit—provided cash now at the cost of the death benefit later.

The practice was ethically controversial from the start. Investors profited from mortality; policyholders gave up legacy wealth for immediate survival needs. But from the policyholder’s perspective, it was a lifeline: the choice was between cash today (viatical) or a death benefit their estate would receive after they were gone. For many, that choice was obvious.

Modern viatical settlements remain niche but legal, regulated in most U.S. states, and primarily serve the chronically ill or terminally ill seeking to self-fund end-of-life care or final wishes.

How pricing works

A policyholder with a $500,000 life insurance policy, diagnosed with stage 4 cancer and a life expectancy of 18 months, might receive an offer of $350,000–$450,000 from a viatical settlement firm. The higher percentage (vs. life settlements for the elderly) reflects near-certainty that the death benefit will be claimed within months.

The buyer’s investment thesis is simple: pay $400,000 today, collect $500,000 in a year or two, realize a 20–50% return, scaled by the timeline. That return attracts specialized investors—often insurance-focused funds and institutional buyers—but the buyer base is smaller than for traditional life settlements because the investment is short-term and mortality-dependent.

Pricing factors include:

• Life expectancy: Shorter expected survival = higher payout percentage.
• Policy type: Policies with higher death benefits command better percentages.
• Medical documentation: Detailed physician reports and medical records reduce uncertainty.
• Liquidity timeline: If the insured is expected to die very soon (months), payout can approach 90%+ of face value.

Tax treatment and the Section 101(g) exclusion

This is where viatical settlements become genuinely complex. Under Section 101(g) of the Internal Revenue Code, proceeds from a viatical settlement can be excluded from taxable income—meaning the payout is tax-free—if the insured is terminally or chronically ill and the buyer is a licensed provider.

Terminally ill: Life expectancy of 2 years or less, certified by a physician.
Chronically ill: Unable to perform at least 2 activities of daily living without assistance, or requiring substantial supervision due to cognitive impairment.

If these conditions are met and the buyer is a state-licensed viatical settlement provider, the policyholder can receive a large cash payment entirely tax-free. This is a remarkable benefit and distinguishes viatical settlements from ordinary capital gains.

However, if the insured’s life expectancy extends beyond the physician’s estimate, the tax treatment can shift. If the insured lives beyond 2 years, the excluded amount may be reconsidered. This creates a perverse incentive: the buyer benefits from quicker death, and the buyer’s actuaries are incentivized to be conservative in life expectancy projections.

Contrast with accelerated death benefits

Some life insurance policies include a rider allowing the policyholder to borrow against or receive a portion of the death benefit if diagnosed with a terminal illness. This is called an accelerated death benefit and is offered by the insurer, not a third party.

An accelerated benefit is simpler and less risky: you deal with your own insurance company, receive better terms (typically 75–100% of the death benefit), and the tax treatment is favorable. However, not all policies offer this rider, and those that do may impose waiting periods or strict definitions of terminal illness.

A viatical settlement is the fallback when no accelerated benefit is available or when the policyholder wants to maximize immediate cash and is willing to navigate a secondary market.

Investor motivations and moral hazard

The investor in a viatical settlement has a financial interest in the policyholder’s death. This creates a theoretical—and occasionally documented—conflict of interest. Scandals have erupted in which unscrupulous investors or settlement firms provided inadequate financial support to policyholders, hastening death to accelerate return on investment.

Modern regulation attempts to curtail this through licensing requirements, disclosure rules, and ethical guidelines. Most U.S. states now regulate viatical settlement providers, requiring licensure and imposing anti-fraud standards.

Still, the fundamental incentive structure remains: the buyer wants death to occur sooner rather than later. Policyholders and their families should approach viatical settlements with eyes open.

Practical considerations

When viatical settlements make sense:

• Terminal diagnosis with substantial medical or end-of-life expenses.
• Desire to use resources while alive rather than leave a death benefit to (possibly distant) heirs.
• No other accessible liquid assets or credit options.
• Policy is large enough to justify the transaction costs (settlement firms typically take 5–15% fees).

When they do not:

• The policyholder has dependents who rely on the death benefit. (Giving it up may impoverish them.)
• The medical prognosis is uncertain; an unexpected recovery would mean the policyholder sacrificed a major asset for no reason.
• Other borrowing options are available (policy loans against cash value, home equity lines of credit).
• The policyholder’s goals can be met through an accelerated death benefit rider.

The regulatory landscape

Viatical settlements are licensed and regulated in approximately 40 U.S. states. Requirements vary widely—some states mandate detailed disclosures, medical underwriting standards, and cooling-off periods; others are lighter-touch. Federal law (Section 101(g)) sets the tax framework but defers to states on licensing and conduct.

Anyone considering a viatical settlement should:

1. Verify the settlement firm is licensed in their state.
2. Obtain a independent medical assessment of life expectancy.
3. Consult a tax advisor about the Section 101(g) implications.
4. Review the settlement agreement carefully; it will restrict your ability to borrow against the policy or change beneficiaries.

See also